European Commission approves AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC)
The European Commission has approved AKEEGA® (niraparib and abiraterone acetate) for patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer, following Phase 3 data showing a significant delay in disease progression and an early survival benefit.
Read more